Insitro has 6 close competitors: Formation Bio, Retro Biosciences, Atomwise.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
InsitroFormation BioAtomwiseBenevolentAIColossal BiosciencesBiotech firm combining automated cellular experiments and population genetics with AI to identify disease drivers and deliver targeted therapeutics.
Insitro competes with 6 companies here: Formation Bio, Retro Biosciences, Atomwise, BenevolentAI, Halda Therapeutics, Colossal Biosciences.
Insitro was last valued at $2.4B (Sep 2021). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The routes section explains what is realistically available for a company at this stage.
No. Insitro was acquired by CombinAble.AI Biotech firm combining automated cellular experiments and population genetics with AI to identify disease drivers and deliver targeted therapeutics; its shares do not trade independently.
The last valuation is $2.4B.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
